Kymera Therapeutics, Inc. Company Profile & Data: stocks, market cap, financials, digital and more

                        
Company
Kymera Therapeutics, Inc.Headquarters: Watertown, 
                        MA, United States
                    
Employees: 141
CEO: Dr. Nello  Mainolfi M.D., Ph.D.

                                    NASDAQ: KYMR
                                
                                            +3.55%
                                            
Market Cap$3.14 Billion

                        USD as of July 1, 2025
                    
                            Market Cap History

Kymera Therapeutics, Inc. Categories

United States Healthcare Biotechnology
United States Healthcare United States Biotechnology

Kymera Therapeutics, Inc. market capitalization over time

Evolution of Kymera Therapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Kymera Therapeutics, Inc.

Top Competitors by Market Capitalization

Industry: Biotechnology

Company	Market Cap (USD)
Novo Nordisk	$309.91 B
Vertex Pharmaceuticals Incorporated	$117.36 B
CSL Limited	$95.75 B
Regeneron Pharmaceuticals, Inc.	$59.14 B
Marinomed Biotech AG	$58.56 B

Sector:

Company	Market Cap (USD)
Lilly	$699.59 B
Johnson & Johnson	$374.29 B
AbbVie	$336.94 B
Novo Nordisk	$309.91 B
UnitedHealth Group	$279.90 B

Detailed Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Tweets by Kymera Therapeutics, Inc.

Financials

Last Financial Reports Date	March 31, 2025
Revenue TTM	$58.9 M
EBITDA	$-271,670,016
Gross Profit TTM	$-212,799,008
Profit Margin	0.00%
Operating Margin	-336.77%
Quarterly Revenue Growth	114.80%